Ustekinumab for Treating Moderately to Severely Active Crohn’s Disease after Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Hodgson, R, Walton, M, Biswas, M et al. (2 more authors) (2018) Ustekinumab for Treating Moderately to Severely Active Crohn’s Disease after Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 36 (4). pp. 387-398. ISSN 1170-7690

Abstract

Metadata

Authors/Creators:
Dates:
  • Published (online): 30 November 2017
  • Published: April 2018
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Translational Medicine (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 06 Dec 2017 14:30
Last Modified: 16 Jul 2018 14:31
Status: Published
Publisher: Springer Verlag
Identification Number: https://doi.org/10.1007/s40273-017-0593-2

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Share / Export

Statistics